Loading
A phase 1/2 trial of Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Servier Bio-Innovation LLC, active and no longer recruiting.
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 1/2 interventional study registered as NCT06162572 by Servier Bio-Innovation LLC, with 102 participants enrolled, started 2024-08-07 and due to reach its primary completion in 2027-04. Interventions recorded: S095018, S095024, S095029, S095018 Recommended Dose Expansion (RDE), S095024 RDE. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.